WO2012165735A1 - Composition pharmaceutique contenant un extrait de riz à base de mycélium de champignon pour traiter le diabète et l'obésité - Google Patents

Composition pharmaceutique contenant un extrait de riz à base de mycélium de champignon pour traiter le diabète et l'obésité Download PDF

Info

Publication number
WO2012165735A1
WO2012165735A1 PCT/KR2011/009508 KR2011009508W WO2012165735A1 WO 2012165735 A1 WO2012165735 A1 WO 2012165735A1 KR 2011009508 W KR2011009508 W KR 2011009508W WO 2012165735 A1 WO2012165735 A1 WO 2012165735A1
Authority
WO
WIPO (PCT)
Prior art keywords
rice
mushroom mycelium
mushrooms
obesity
pharmaceutical composition
Prior art date
Application number
PCT/KR2011/009508
Other languages
English (en)
Korean (ko)
Inventor
백성현
김해섭
유제헌
임한수
Original Assignee
(주)해뜰날
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)해뜰날 filed Critical (주)해뜰날
Publication of WO2012165735A1 publication Critical patent/WO2012165735A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment

Definitions

  • the present invention relates to a pharmaceutical composition for treating diabetes or obesity and health food comprising an extract of mushroom mycelial rice as an active ingredient.
  • Germination of grains relaxes the defective structure of organic matter, making it soft and easy to digest in the body when eaten. In other words, when germinated, the grains loosen the bond structure that was hard to nourish new life, and as a result, the grain becomes soft. Soaking brown rice in water for more than a day and then softening it is because of the subtle differentiation caused by germination.
  • the cheap germinated brown rice ingredients that are cheap brown rice are known as gamma-originol, vitamins, amino acids, fatty acids, dietary fiber, SOD, etc.
  • the ingredients there are also new ingredients such as arabinoxy, which are attracting the attention of academics.
  • germinated grains can be easily digested like fermented foods, increase the activity of enzymes in the body, and obtain various substances that have beneficial effects on the human body. After all, germinating grain is another breakthrough that can maximize the efficacy of food along with fermentation. In addition, by fully utilizing the usefulness of grain, it is an innovative way to heal disease and achieve disease-free longevity.
  • mushrooms are a kind of goose pie, with a group of umbrella-shaped caps and sacks. These mushrooms are composed of fruit bodies with mycelium (Mycelium) and spores (spore) for reproduction. Compared to general plants, mycelium is root, stem and leaf, and fruit body is flower.
  • Mycelium mycelium
  • spore spore
  • the fluffy, thin thread-like mycelium is white in organic matter such as humus and trees. They are parasitic or by-productive with fungi.
  • the spores are hard and coated so that it is difficult to absorb digestion even if you eat mushrooms, spores germinate in the medium to become the first mycelium, and the compatible hyphae are cellular fusion with each other to become the second mycelia, while ingesting sufficient nutrients.
  • the mycelium contains four times more nutrients than fruiting bodies, proteins, amino acids, vitamins, minerals, and various enzymes, so that the nutrition can be balanced enough to be reported.
  • the mystery of the mycelium hides in the mycelium because the mycelium contains 50-60 times more medicinal components such as anticancer ingredients and immune enhancing components.
  • the conventional gasols described above have the disadvantage that the components such as beta glucan are significantly lowered by culturing the mushroom mycelium only by cultivating the mushroom bacteria in grains that have been germinated or grown in the rice seed state by using only the nutrients in the grain.
  • the method of immersing the mushroom extract can not extract the active ingredient completely during the extraction of the mushroom extract, the extract is not absorbed well in the grain, there is a big problem that the extract is washed in the washing process even if the grain is coated on the outer wall .
  • the present applicant controls sterilized grains having no water content in patent application No. 2008-0120516 and then sterilizes to kill off microorganisms that cause off-flavor, and when inoculated with mushroom mycelium, the mushroom mycelium is the outer shell or pores of the grain. Penetrating through the surface of the grains through the decomposition of lignin, cellulose, hemicellulose and other fibers to grow by using a lot of ingredients such as beta glucan was found and filed.
  • the present inventors have conducted research and efforts to prepare a therapeutic agent for metabolic diseases such as diabetes and obesity, and have completed the present invention by finding that the extract of mushroom mycelial rice inoculated with a specific mushroom mycelium exhibits excellent anti-diabetic and anti-obesity effects. It became.
  • an object of the present invention is to provide a pharmaceutical composition for the treatment of diabetes or obesity comprising the extract of mushroom mycelium rice as an active ingredient.
  • the present invention is to provide a health food for diabetes prevention or weight control comprising an extract of mushroom mycelium rice.
  • the present invention is a.
  • composition for treating diabetes or obesity comprising the extract of the mushroom mycelium rice prepared by the manufacturing method comprising as an active ingredient.
  • the present invention is characterized by another health food for diabetes prevention or weight control comprising the extract of the mushroom mycelium rice as an active ingredient.
  • Mushroom mycelium rice of the present invention contains a large amount of nutrients, including beta glucan, it is easy to store and can be stored for a long time by containing the appropriate moisture.
  • the extract of the mushroom mycelium rice shows an excellent anti-diabetic and anti-obesity effect, it can be widely used for the treatment or prevention of metabolic diseases such as diabetes or obesity.
  • 3 is a graph confirming the fat accumulation inhibitory effect of the situation mushroom mycelium rice.
  • Figure 4 is a graph confirming the fat accumulation inhibitory effect of shiitake mushroom mycelium rice.
  • FIG. 6 is a graph confirming the CETP inhibitory activity of shiitake mushroom mycelium rice.
  • the present invention is characterized in that the pharmaceutical composition for treating diabetes or non-minin containing the extract of mushroom mycelium as an active ingredient.
  • Mushrooms are ingested and grown by secreting enzymes such as starch, glycosides, proteins and minerals, as well as cell wall components such as cellulose, lignin, hemicellulose, which are the main texts of wood and sawdust.
  • enzymes such as starch, glycosides, proteins and minerals
  • cell wall components such as cellulose, lignin, hemicellulose, which are the main texts of wood and sawdust.
  • cellulose, lignin, hemicellulose contained in the shell and the shell, and mushroom nutrients can use many nutrients such as amino acids, sugars, vitamins and minerals during the germination process.
  • the manufacturing process of the mushroom mycelium rice is as follows.
  • a pressure of 10 ⁇ 20kg / cm2 for 1 to 2 seconds in order to generate a larger gap between the shell and the grain in the germinated rice. This is due to the pressing of the grain, which results in larger grain and shell gaps. If the pores of the shell and the grain is large, the mycelia are easily infiltrated when inoculated with the mushroom mycelium, so that the grain can grow quickly.
  • the rice When the rice is immersed in water, pores are generated, and in particular, when the germination of rice is made, the size of the pores is much larger, and microorganisms that cause off-flavor are produced.
  • the microorganisms are killed through sterilization.
  • the grain containing water expands to push the outer shell and voids occur between the outer shell and the grain. If the moisture content exceeds 50%, the grain rapidly expands during sterilization and the outer shell bursts. The shape of the grains is deformed and hard to be milled, and the problems arise that the grains are brought to each other to cause significant difficulties in cultivation of the mycelium.
  • soy flour or corn flour is added to 100 parts by weight of rice, and then killed, the ability to decompose cellulose, such as cellulose, hemicellulose, and lignin, which is contained in the shell, is poor.
  • Mushroom mycelia are supplied with insufficient nutrients through rice bran, soy flour or oak powder to help mycelia adhere to the skin.
  • mushroom mycelium is inoculated into sterile rice.
  • the mushroom mycelium is selected from the group consisting of shiitake mushrooms, situation mushrooms, ganoderma lucidum mushrooms, fueryeong, agaricus, roe deer, cordyceps, cloud fingering, spirits, zelkova, spinning top, birds, flowers, leaf mushrooms and chaga, preferably shiitake Use mushrooms, situation mushrooms or chaga.
  • the mushroom mycelium is preferably incubated for 10 to 20 days after inoculation in a separate liquid medium.
  • incubating the temperature is preferably in the range of 15 ⁇ 35 °C, outside the above range is slow growth of the mycelium.
  • the mushroom mycelium rice is finally dried, preferably the water content is adjusted to 15 to 17%.
  • the drying process is made in a grain dryer attached to an automatic moisture meter, and adjusts the water content to 15 to 17%.
  • Mushroom mycelium rice extract of the present invention can be used in the conventional extraction methods in the art, such as the method using an extraction device, preferably warm It may be prepared by reflux extraction or extraction at room temperature, but is not limited thereto.
  • the number of extraction is preferably 1 to 5 times, and more preferably 3 times of extraction, but is not limited thereto.
  • the extract is preferably extracted using water, an alcohol having 1 to 6 carbon atoms or a mixed solvent thereof, and most preferably extracted with methanol or ethanol.
  • the mushroom mycelial rice extract of the present invention exhibits anti-diabetic activity by inhibiting the activity of PTP1B, which is known as a negative regulator of insulin signaling system, and can be used for the treatment of diabetes mellitus, and also inhibits fat accumulation and cholesterol ester transfer protein ( Cholesteryl ester transfer protein (CETP) can be inhibited and used to treat obesity.
  • PTP1B which is known as a negative regulator of insulin signaling system
  • CETP Cholesteryl ester transfer protein
  • the present invention provides a health food for diabetes prevention or weight control containing the mushroom mycelium rice extract as an active ingredient.
  • Examples of foods to which the above-mentioned substances may be added include dairy products including drinks, meat, sausages, breads, biscuits, rice cakes, chocolates, candy, snacks, confectionery, pizza, ramen, other noodles, gums and ice cream, various soups, Beverages, alcoholic beverages and vitamin complexes and the like, and include all of the health foods in the conventional sense.
  • the mushroom mycelium is pre-cultured and stored in the PDA (Potato dextrose agar) culture site, the mushroom spawn in the Department of Applied Microorganisms, Rural Development Administration, Agricultural Science and Technology Institute, Chonbuk Agricultural Research and Development Institute, and contains 3% by weight of sugar and 0.3% by weight of soybean meal. Inoculated into sterilized liquid medium.
  • PDA Pantotato dextrose agar
  • Table 1 shows the culture state of the mycelia according to the mushroom mycelium.
  • the germinated rice was placed in a sieve or net to remove moisture, and then adjusted to a moisture content of 35% using a grain moisture meter, and then placed in a sterilizable 1 liter 18 glass bottle.
  • the germinated rice was sterilized by maintaining the glass bottle at 121 ° C. for 90 minutes. Thereafter, inoculated with the mushroom mycelium cultured in Example 1 in a glass bottle containing sterilized rice and incubated for 20 days. Finally, the rice mycelium cultured mushroom mycelium was dried to obtain a mushroom mycelium grain.
  • Table 2 shows the culture state of the mycelia according to the mushroom mycelium.
  • the content of beta glucan in mushroom mycelium grains and 9-minute sea bream and pottery by-products was measured using the situation mushroom mycelium.
  • After immersing brown rice in water for 8 hours, sterilizing for 30 minutes at 121 °C, inoculated with the mycelium mushroom mycelium and incubated for 10-20 days at 25 °C mushroom brown rice and the content of beta glucan in the situation mushroom cultured in oak was measured and compared, and the results are shown in Table 3 below.
  • Example 2 When sterilized in Example 2, 5 parts by weight of rice bran, soy flour or oak powder was added to 100 parts by weight of the germinated grains, and the mycelium culture state in the rice hull was shown in Table 4 below.
  • the general components of the situation mushroom mycelium rice and shiitake mushroom mycelium of Example 2 were measured according to the A.O.A.C. method, and are shown in Table 5 below.
  • moisture is the atmospheric pressure drying method
  • crude protein is the Kjeldakl method using the automatic nitrogen distillation unit (KJELTEC 2200 SYSTEM, Foss, Sweden)
  • crude fat is the Soxhlet method using the automatic fat extraction unit (SOXTEC AVANTI 2055 SYSTEM, Foss, Sweden).
  • Inquiry was measured by the dry painting method. Crude carbohydrate was obtained by subtracting 100 from the sum of moisture, crude fat, crude protein and crude ash.
  • Electron-donating activity was immediately determined using the Blois method. In other words, 3 ml of 0.0001M 1,1-di-phenyl-2-picrylhydrazyl (DPPH) solution (dissolved in 99.9% methanol) was added to 0.2 ml of the sample, followed by 10 seconds of stirring, followed by reaction for 10 minutes to absorb absorbance at 525 nm. The decrease value was measured, and the electron donating ability is expressed as a percentage of the absorbance difference between the sample addition and the non-addition as shown in Equation 1 below.
  • DPPH 1,1-di-phenyl-2-picrylhydrazyl
  • 900 ⁇ l of distilled water was added to 100 ⁇ l of sample, and 0.2N Folin-Ciocalteu's phenolic reagent was added thereto and mixed. Thereafter, the mixture was allowed to stand at room temperature for 3 minutes, and then 1 ml of 1% sodium carbonate solution was added thereto, mixed, shaken, and left at room temperature for 1 hour to measure absorbance at 760 nm.
  • the standard material is treated in the same way as the sample using tannic acid to prepare a standard curve, and then the concentration of the phenolic compound in the sample is calculated in consideration of the dilution factor and the like by reading the concentration of the standard substance for absorbance of the sample. It was.
  • the powder was used to identify PTP1B inhibitory activity known as a negative regulator of the insulin signal transduction system.
  • PTP1B content was measured using a PTP1B fluorometric assay kit (ABNOVA, USA).
  • ABNOVA PTP1B fluorometric assay kit
  • 30 ⁇ l of distilled water, 30 ⁇ l of 10X PTP assay buffer, and 5 ⁇ l of 10X fluoro-phospho-substrate were added to each well of the 96 well-plate, followed by incubation for 15 minutes at room temperature by adding recombinant PTP1B.
  • 20 ⁇ l of developing buffer was added to each well, followed by incubation at room temperature for 15 minutes, and 25 ⁇ l of stopsolution was added to stop the reaction.
  • Fluorescence intensity was measured at an excitation wavelength of 502 nm and a measurement wavelength of 530 nm, and is calculated as in Equation 2 below.
  • the situation mushroom mycelium rice showed a significant inhibitory effect at a statistically p ⁇ 0.05 level at 1 ⁇ g / ml compared to the control, 3, 10, 30, 100, 300, 1,000 ⁇ g / In ml, significant inhibitory effect was observed at p ⁇ 0.01 level.
  • shiitake mushroom mycelium rice showed a significant inhibitory effect at the p ⁇ 0.01 level statistically at 1 ⁇ 1,000 ⁇ g / ml compared to the control.
  • the extract of mushroom mycelial rice is expected to increase the action of insulin and delay the absorption of glucose by preventing the PTP1B enzyme involved in the dephosphorylation of insulin signaling in body tissues, thereby preventing or improving diabetes. It became.
  • a 0.35 g Oil Red O reagent was dissolved in 100 mL isopropanol and filtered to obtain a stock solution, and a working solution was prepared by mixing 60% by weight of the stock solution with 40% by weight of distilled water.
  • a working solution was prepared by mixing 60% by weight of the stock solution with 40% by weight of distilled water.
  • the medium was removed and the cell culture was washed with PBS, and then fixed with 5 ⁇ l of 10% formaldehyde and fixed for 5 minutes. Again, 500 ⁇ l of 10% formaldehyde was added to each well and fixed for 1 hour. After removing formaldehyde and washing with distilled water, 500 ⁇ l of the working solution was placed in each well, dyed at room temperature for 30 minutes, and washed three times with distilled water.
  • the stained cells were observed under a microscope and 100% isopropanol was added to elute lipids accumulated in the cells.
  • the cells were transferred to 96-well plates and absorbed at 500 nm to evaluate the degree of lipid accumulation.
  • the degree of lipid accumulation according to the treatment of each sample extract is shown in FIGS. 3 and 4.
  • CETP content was measured using a CETP inhibitor assay kit (BioVision, USA). After 160 ⁇ L of the sample was put into a 96 well plate, 3 ⁇ L of Rabbit Serum was added and reacted. 10 ⁇ L of Donor Molecule, 10 ⁇ L of Acceptor Molecule, and 10 ⁇ CETP Assay Buffer were added to each well and incubated at 37 ° C. for 30 minutes. Fluorescence intensity was measured at an excitation wavelength of 465 nm and a measurement wavelength of 535 nm. The results of measuring CETP inhibitory activity are shown in FIGS. 5 and 6, respectively.
  • the situation mushroom mycelial rice had a concentration-dependent inhibitory effect, and showed a significant inhibitory effect at p ⁇ 0.05 level at 100 ⁇ g / mL, and significant at p ⁇ 0.01 level at 300 ⁇ g / mL.
  • One inhibitory effect was shown.
  • the shiitake mushroom mycelium rice had a concentration-dependent inhibitory effect, and showed a significant inhibitory effect at p ⁇ 0.05 level at 30 ⁇ g / mL, and a p ⁇ 0.01 level at 100 and 300 ⁇ g / mL. Showed significant inhibitory effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition pharmaceutique et un aliment sain contenant un extrait de riz à base de mycélium de champignon pour traiter le diabète et l'obésité. L'extrait de riz à base de mycélium de champignon en tant que principe actif de la présente invention contient une quantité significative d'ingrédients nutritionnels, tels que du béta-glucane, est facile à conserver du fait qu'il a une quantité d'humidité appropriée, et peut être conservé à long terme. L'extrait de riz à base de mycélium de champignon, en particulier, présente des effets supérieurs contre le diabète et contre l'obésité et peut ainsi être largement utilisé pour traiter ou prévenir des maladies métaboliques, telles que le diabète ou l'obésité.
PCT/KR2011/009508 2011-05-27 2011-12-09 Composition pharmaceutique contenant un extrait de riz à base de mycélium de champignon pour traiter le diabète et l'obésité WO2012165735A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0050897 2011-05-27
KR1020110050897A KR20120132207A (ko) 2011-05-27 2011-05-27 버섯균사체쌀 추출물을 포함하는 당뇨병 또는 비만 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
WO2012165735A1 true WO2012165735A1 (fr) 2012-12-06

Family

ID=47259553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/009508 WO2012165735A1 (fr) 2011-05-27 2011-12-09 Composition pharmaceutique contenant un extrait de riz à base de mycélium de champignon pour traiter le diabète et l'obésité

Country Status (2)

Country Link
KR (1) KR20120132207A (fr)
WO (1) WO2012165735A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10493123B2 (en) * 2014-03-19 2019-12-03 YISSUM RESEARCH DEVELOPMENT COMPANY OF of The Hebrew University of Jerusalem LTD. Method of treating overweight or obesity comprising administering a pleurotus ostreatus mushroom extract or a composition comprising a pleurotus ostretus mushroom extract

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101632251B1 (ko) * 2013-12-31 2016-06-21 순천대학교 산학협력단 표고버섯균사체쌀이 첨가된 해물죽 및 이의 제조방법
KR102071696B1 (ko) * 2018-04-25 2020-01-30 재단법인 장흥군버섯산업연구원 표고 균사체 배양미를 이용한 쌀빵의 제조방법
KR102271933B1 (ko) * 2019-10-29 2021-07-05 주식회사 기운찬 버섯 복합배양 균사체를 함유하는 혈당 조절용 조성물의 제조방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020069859A (ko) * 2001-02-28 2002-09-05 (주) 피앤에프바이오텍 액체종균을 활용한 생육기간 단축의 버섯균사체곡물의제조방법
KR20020096575A (ko) * 2001-06-21 2002-12-31 송재만 고함량의 미량무기물을 함유하는 버섯 균사체의 생산방법및 그 산물
KR20040062814A (ko) * 2003-01-03 2004-07-09 김정옥 혈당강하효과를 지닌 버섯균사체추출물 제조 방법
KR20050040520A (ko) * 2003-10-29 2005-05-03 청일잠비농산 상황버섯 균사체 추출물을 이용한 당뇨치료용 소재
KR20100062085A (ko) * 2008-12-01 2010-06-10 (주) 해뜰날 버섯균사체곡물 및 이의 제조방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020069859A (ko) * 2001-02-28 2002-09-05 (주) 피앤에프바이오텍 액체종균을 활용한 생육기간 단축의 버섯균사체곡물의제조방법
KR20020096575A (ko) * 2001-06-21 2002-12-31 송재만 고함량의 미량무기물을 함유하는 버섯 균사체의 생산방법및 그 산물
KR20040062814A (ko) * 2003-01-03 2004-07-09 김정옥 혈당강하효과를 지닌 버섯균사체추출물 제조 방법
KR20050040520A (ko) * 2003-10-29 2005-05-03 청일잠비농산 상황버섯 균사체 추출물을 이용한 당뇨치료용 소재
KR20100062085A (ko) * 2008-12-01 2010-06-10 (주) 해뜰날 버섯균사체곡물 및 이의 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHOI, HEE DON ET AL.: "Hypoglycemic Effects of Basidiomycetes Mycelia and Cereals Fermented with Basidiomycetes", JOURNAL OF THE KOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION, vol. 36, no. 10, 2007, pages 1257 - 1262 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10493123B2 (en) * 2014-03-19 2019-12-03 YISSUM RESEARCH DEVELOPMENT COMPANY OF of The Hebrew University of Jerusalem LTD. Method of treating overweight or obesity comprising administering a pleurotus ostreatus mushroom extract or a composition comprising a pleurotus ostretus mushroom extract
US10716825B2 (en) 2014-03-19 2020-07-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating a liver disease comprising administering ostreolysin orfunctionally related variant thereof

Also Published As

Publication number Publication date
KR20120132207A (ko) 2012-12-05

Similar Documents

Publication Publication Date Title
KR20120132208A (ko) 버섯균사체쌀과 해조류를 이용한 발효주의 제조방법
KR20110089107A (ko) 쿠메스트롤 생산 방법 및 그에 의해 생산된 쿠메스트롤
WO2012165735A1 (fr) Composition pharmaceutique contenant un extrait de riz à base de mycélium de champignon pour traiter le diabète et l'obésité
KR20100092786A (ko) 천연 고미성분을 유산균 발효시킨 멀티형 혈당강하용 식품 조성물 및 그 제조 방법
CN103045490B (zh) 发芽糙米制备的功能红曲及方法
KR100803998B1 (ko) 진피발효추출물, 그 제조방법 및 건강기능식품
KR100931526B1 (ko) 칠황버섯 균사체를 이용한 발효식품 및 그 제조방법
CN112691125B (zh) 一种用于美白或者抗衰老的药物组合物及其制备方法、护肤品
KR20160059137A (ko) 유산균 및 천연효소를 이용한 발효삼채 제조 및 숙취해소용 혼합음료 제조방법
KR101993441B1 (ko) 플라보노이드를 함유하는 기능성 발효현미의 제조방법
CN115141785B (zh) 一种枯草芽孢杆菌及其在甘蓝种植中的应用
CN116515586A (zh) 具有抗炎、抗氧化特性的苦荞养生酒及其制备方法
CN115634241A (zh) 一种山东灵芝提取物的制备方法及其在制备降血糖药物中的应用
CN107929122B (zh) 一种丝瓜酵素混合液及其制备方法
JP4912720B2 (ja) 茸由来破骨細胞形成阻害剤
KR100663876B1 (ko) 생리활성을 갖는 버섯균사체의 배양물
KR100801435B1 (ko) 높은 유해 산소 제거 능력을 갖는 차가버섯 발효 음료의 제조방법
KR20130008823A (ko) 천연 약재 추출물의 항산화 활성을 향상시키는 방법, 및 이 방법에 의해 수득되는 추출물을 함유하는 노화방지용 화장료 조성물 또는 항산화성 및 항염증성 의약 조성물
KR100945670B1 (ko) 청국장 분말을 포함하는 건강 식품 조성물
KR101381950B1 (ko) 감잎 발효차 및 이의 제조방법
WO2020091192A9 (fr) Produit de fermentation mixte mûri de ginseng cultivé de manière sauvage dans lequel du ginsénoside absorbable dans le corps humain et l'acide gras oméga-6 sont augmentés, et son procédé de préparation
KR102483343B1 (ko) 기능성 성분이 증진된 꽃송이버섯 추출물
KR20130131875A (ko) 미생물 발효로 추출되는 제주송이 발효배양액과 이를 이용하여 양액재배된 기능성 식물과 그 재배방법
KR20140084502A (ko) 알로에와 울금을 이용한 혼합발효물을 유효성분으로 하는 간 기능 개선용 조성물과 그 제조방법 및 이를 이용한 간 기능 개선용 제제
KR20040051783A (ko) 홍국균으로 발효시킨 메밀

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11866698

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11866698

Country of ref document: EP

Kind code of ref document: A1